Treatment planning and delivery of involved field radiotherapy in advanced Hodgkin's disease: Results from a questionnaire-based audit for the UK Stanford V regimen vs ABVD clinical trial quality assurance programme (ISRCTN 64141244)

British Journal of Radiology

Volumn 80, Issue 958, 2007, Pages 816-821

  Diez, Patricia ^a   Hoskin, P J ^a   Aird, E G A ^a  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; ARTICLE; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSIMETRY; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PATIENT POSITIONING; QUALITY CONTROL; QUESTIONNAIRE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; TREATMENT PLANNING; UNITED KINGDOM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GREAT BRITAIN; HODGKIN DISEASE; HUMANS; MECHLORETHAMINE; PREDNISONE; QUALITY ASSURANCE, HEALTH CARE; VINBLASTINE; VINCRISTINE;

EID: 36748999443     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/56458296     Document Type: Article

References (8)

1. Winfield E, Deighton A, Venables K, Hoskin PJ, Aird EG. Survey of UK breast radiotherapy techniques: background prior to the introduction of the quality assurance programme for the START (standardisation of radiotherapy) trial in breast cancer. Clin Oncol (R Coll Radiol) 2002;14:267-71.
2. Mayles WPM, Moore AR, Aird EG, Bidmead AM, Dearnaley DP, Griffiths SE, et al. Questionnaire based quality assurance for the RT01 trial of dose escalation in conformai radiotherapy for prostate cancer. Radiother Oncol 2004;74: 199-207.
3. Hoskin PJ, Bradshaw A. Late complications of mantle radiotherapy for Hodgkin's disease. Ann Oncol 1996;7(Suppl 3):119.
4. Hoskin PJ, Smith P, Maughan TS, Gilson D, Vernon C, Syndikus I, et al. Long term results of a randomised trial of involved field radiotherapy versus extended field radiotherapy in stage I and II Hodgkin lymphoma. Clin Oncol (R Coll Radiol) 2005;17:47-53.
5. Chisesi T, Federico M, Levis A, Deliliers GL, Gobbi PG, Sentini G, et al. ABVD versus Stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial. Ann Oncol 2002;13(Suppl 1):102-6.
6. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31:1860-1.
7. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7:1630-6.
8. Yahalom J, Mauch P. The involved field is back: issues in delineating the radiation field in Hodgkin's disease. Ann Oncol 2002;13(Suppl 1):79-83.